Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00898313 · ClinicalTrials.gov registry record
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- 4,000
- Enrollment target
NCT00898313 is a clinical trial that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 4,000 participants.
The verdict
NCT00898313 is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
Study Summary
RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.
Interventions
- OTHER biologic sample preservation procedure
- GENETIC comparative genomic hybridization
- GENETIC gene expression microarray analysis
- GENETIC proteomic profiling analysis
- PROCEDURE nasal brushing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2003-12 |
| Est. Completion | 2027-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00898313
The ClinicalTrials.gov registry entry for NCT00898313 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which biologic sample preservation procedure is the first listed.
NCT00898313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00898313 about?
NCT00898313 is a clinical study titled "Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer". RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at molecular predictors of...
What is the current status of trial NCT00898313?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2003-12. Estimated completion is 2027-01-31.
What interventions are being tested in trial NCT00898313?
The interventions under investigation include: biologic sample preservation procedure (OTHER), comparative genomic hybridization (GENETIC), gene expression microarray analysis (GENETIC), proteomic profiling analysis (GENETIC), nasal brushing (PROCEDURE).
Who is sponsoring clinical trial NCT00898313?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.